TransThera: FDA approves TransThera's IND application for B-Cell lymphoma treatment
TT-01488 can potentially address the acquired resistance mutation caused by various covalent BTK inhibitors in the market. The post FDA approves TransThera's IND application for B-Cell lymphoma treatment appeared first on Pharmaceutical Technology.
Read full article »
TransThera is a China-based biotechnology firm that researches, develops and commercializes small molecule drugs for oncology, cardiovascular, and inflammatory diseases.
Read more